Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | NNMT | P40261 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29618255 | 1.00 | MEN1 (0.68) | MEN1KMT2ANNMTL3MBTL1NPSR1 | |
| SCHEMBL4120256 | 0.91 | MEN1 (0.58) | MEN1KMT2ANNMTL3MBTL1NPSR1 | |
| Trifluoroacetic Acid SCHEMBL29618259 | 0.88 | MEN1 (0.59) | MEN1KMT2ANNMTL3MBTL1NPSR1 | |
| Oxiniacic Acid SCHEMBL129209 | 0.81 | MEN1 (1.00) | MEN1KMT2AL3MBTL1CYP3A4TSHR | |
| Oxiniacic Acid SCHEMBL29766756 | 0.81 | MEN1 (1.00) | MEN1KMT2AL3MBTL1CYP3A4TSHR | |
| SCHEMBL2772084 | 0.79 | MEN1 (0.68) | MEN1KMT2ANNMTL3MBTL1CYP3A4 | |
| SCHEMBL9083270 | 0.79 | MEN1 (0.68) | MEN1KMT2ANNMTL3MBTL1CYP3A4 | |
| SCHEMBL5699279 | 0.79 | KMT2A (0.57) | MEN1KMT2ANNMTL3MBTL1RECQL | |
| SCHEMBL212234 | 0.79 | MEN1 (0.68) | MEN1KMT2ANNMTL3MBTL1MAPT | |
| SCHEMBL25846405 | 0.79 | MEN1 (0.57) | MEN1KMT2ANNMTL3MBTL1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1647 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| US-20240290431-A1 | BIOMARKER AND DIAGNOSIS SYSTEM FOR COLORECTAL CANCER DETECTION | HANGZHOU CALIBRA DIAGNOSTICS CO LTD (CN) | 2024-08-29 | — | — | US | claimed |
| WO-2023195790-A1 | METHOD FOR MANUFACTURING BIOMATERIAL FOR TISSUE REPAIR WITH EXCELLENT SAFETY | ㈜아크로스 | 2023-10-12 | — | — | WO | claimed |
| WO-2023156070-A1 | COSMETIC COMPOSITION | THE BOOTS COMPANY PLC (GB) | 2023-08-24 | — | — | WO | claimed |
| WO-2023156069-A1 | COSMETIC COMPOSITION COMPRISING EXTRACT OF OPHIOPOGON JAPONICUS AND AT LEAST ONE CERAMIDE | THE BOOTS COMPANY PLC (GB) | 2023-08-24 | — | — | WO | claimed |
| WO-2023144235-A1 | METHODS FOR MONITORING AND TREATING WARBURG EFFECT IN PATIENTS WITH PI3K-RELATED DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-08-03 | — | — | WO | claimed |
| US-20230204604-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-06-29 | — | — | US | claimed |
| US-20230157939-A1 | PERSONAL CARE COMPOSITIONS WITH ENHANCED SOLUBILITY ACTIVES | CONOPCO, INC., D/B/A UNILEVER (US) | 2023-05-25 | — | — | US | claimed |
| US-20230101362-A1 | RNA STABILIZATION | TEAM MEDICAL LLC | 2023-03-30 | — | — | US | claimed |
| EP-4142677-A1 | PERSONAL CARE COMPOSITIONS WITH ENHANCED SOLUBILITY ACTIVES | Unilever IP Holdings B.V. (NL) | 2023-03-08 | — | — | EP | claimed |
| WO-1999006052-A1 | METHODS OF PRETREATING HYPERLIPIDEMIC INDIVIDUALS WITH A FLUSH INHIBITING AGENT PRIOR TO THE START OF SINGLE DAILY DOSE NICOTINIC ACID THERAPY TO REDUCE FLUSHING PROVOKED BY NICOTINIC ACID | KOS PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | claimed |
| WO-1999006035-A2 | COMBINATIONS OF HMG-CoA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT | KOS PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | claimed |
| US-5512588-A | ANTIULCER AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-30 | — | — | US | claimed |
| US-5472687-A | A water in oil or oil in water emulsion for treating hair loss ; free of hypotensive agent, side-effect reduction | PROCTOR PETER H (US) | 1995-12-05 | — | — | US | claimed |
| EP-0327263-B1 | Hair growth stimulation with nitroxide and other radicals | PROCTOR PETER H (US) | 1994-09-07 | — | — | EP | claimed |
| EP-0355612-B1 | Furylthiazole derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-07-27 | — | — | EP | claimed |
| US-5308857-A | Antiulcer agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-05-03 | — | — | US | claimed |
| EP-0355612-A2 | Furylthiazole derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-02-28 | — | — | EP | claimed |
| US-4568628-A | Water developable diazo printing plate composition with quaternary nitrogen stabilizer | POLYCHROME CORPORATION (US) | 1986-02-04 | — | — | US | claimed |
| US-4514408-A | INHIBITORS OF GASTRIC SECRETION | SANOFI (FR) | 1985-04-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230157939-A1 | PERSONAL CARE COMPOSITIONS WITH ENHANCED SOLUBILITY ACTIVES | CUTA, CBS, SLC7A11 | MEN1 3851/4885KMT2A 2100/4885NNMT 124/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | MEN1 3658/4885KMT2A 119/4885NNMT 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.